These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Yellow fever vaccination: some thoughts on how much is enough [Vaccine 23 (2005) 3908-3914]. Martins RM; Galler R; Freire MS; Camacho LA; de Lourdes S Maia M; Homma A Vaccine; 2007 Jan; 25(1):10-1. PubMed ID: 16448728 [TBL] [Abstract][Full Text] [Related]
8. Active surveillance for influenza vaccine adverse events: the integrated vaccine surveillance system. Newes-Adeyi G; Greece J; Bozeman S; Walker DK; Lewis F; Gidudu J Vaccine; 2012 Feb; 30(6):1050-5. PubMed ID: 22200501 [TBL] [Abstract][Full Text] [Related]
9. Internet-based reporting to the vaccine adverse event reporting system: a more timely and complete way for providers to support vaccine safety. Haber P; Iskander J; Walton K; Campbell SR; Kohl KS Pediatrics; 2011 May; 127 Suppl 1():S39-44. PubMed ID: 21502243 [TBL] [Abstract][Full Text] [Related]
10. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005. Fernandes GC; Camacho LA; Sá Carvalho M; Batista M; de Almeida SM Vaccine; 2007 Apr; 25(16):3124-8. PubMed ID: 17316927 [TBL] [Abstract][Full Text] [Related]
11. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of vaccination against yellow fever of persons traveling to endemic areas]. Dabrowska MM; Flisiak R Przegl Epidemiol; 2010; 64(2):319-22. PubMed ID: 20731245 [TBL] [Abstract][Full Text] [Related]
13. Yellow fever - prevention in travellers. Neilson AA; Mayer CA Aust Fam Physician; 2010 Aug; 39(8):570-3. PubMed ID: 20877751 [TBL] [Abstract][Full Text] [Related]
14. Typhoid fever in travelers: who should be targeted for prevention? Steinberg EB; Bishop R; Haber P; Dempsey AF; Hoekstra RM; Nelson JM; Ackers M; Calugar A; Mintz ED Clin Infect Dis; 2004 Jul; 39(2):186-91. PubMed ID: 15307027 [TBL] [Abstract][Full Text] [Related]
15. Viscerotropic disease following yellow fever vaccination in Peru. Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215 [TBL] [Abstract][Full Text] [Related]
16. Age-related risk of adverse events following yellow fever vaccination in Australia. Lawrence GL; Burgess MA; Kass RB Commun Dis Intell Q Rep; 2004; 28(2):244-8. PubMed ID: 15460963 [TBL] [Abstract][Full Text] [Related]
18. Safety of Typhim Vi vaccine in a postmarketing observational study. Marcus LC; Froeschle JE; Hill DR; Wolfe MS; Maus D; Connor B; Acosta AM; Rensimer ER; Roberts A; Dardick K J Travel Med; 2007; 14(6):386-91. PubMed ID: 17995534 [TBL] [Abstract][Full Text] [Related]
19. Acceptability of Internet adverse event self-reporting for pandemic and seasonal influenza immunization among health care workers. Lapphra K; Dobson S; Bettinger JA Vaccine; 2010 Aug; 28(38):6199-202. PubMed ID: 20654668 [TBL] [Abstract][Full Text] [Related]
20. Short report: Incidence of yellow fever vaccine-associated neurotropic disease. Guimard T; Minjolle S; Polard E; Fily F; Zeller H; Michelet C; Tattevin P Am J Trop Med Hyg; 2009 Dec; 81(6):1141-3. PubMed ID: 19996449 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]